Viewpoints on future dissemination of take-home naloxone: opportunities and challenges

Similar documents
EMCDDA-update HIV/HCV among people who inject drugs: situation and response

New trends in harm reduction in Europe: progress made challenges ahead

Most recent data, analyses and feed-back from the 2016 DRID national updates

HIV/AIDS Think Tank meeting: EMCDDA report. Roland Simon, Klaudia Palczak, EMCDDA Luxembourg, 7 July 2015

Overview of drug-induced deaths in Europe - What does the data tell us?

Opioid education programs and nasal naloxone rescue kits

Methadone related deaths in Europe: analyses using the methadone-od4 index in four countries

Present and potential perspectives for information on alcohol use in the EU

Trends in injecting drug use in Europe

NPS use, harms and health responses to NPS in Europe: findings form multi-method studies

Preventing Avoidable Deaths: A Narrative Review and Recommendations On Opioid Overdose

Integrated harm reduction services for drug users and homeless people. Katrin Schiffer

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

The impact of economic recession on drug users and drug treatment

A review of drug-related deaths in seven Northern European countries

The Norwegian experience: Changing models of treatment and services within addictions in Norway

Feasibility study on drug consumption rooms in Belgium (DRUGROOM) Summary

PERSPECTIVES ON DRUGS Preventing overdose deaths in Europe

The issues facing Europe

Perspectives for information on alcohol use in the EU

Annual report 2012: the state of the drugs problem in Europe

Fentanils in Europe: perspective from the EU EWS

Tramadol-related deaths

Intervention from the World Health Organization

Improving Clinical Responses to Drug-Related Deaths. Presented by: Dr Prun Bijral Medical Director Date: 15 th November 2017

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

8.0 Take Home Naloxone

PERSPECTIVES ON DRUGS Preventing overdose deaths in Europe

Balancing access, quality and prevention of diversion of OST in Europe: a comparative analysis

Sure you can quit drugs - but first you have to survive

Harm Reduction 10/17/2018. Topics for Today. Working Definition of Harm Reduction

Drug Consumption Rooms Worldwide

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

TDI 3.0 implementation. TDI Prevalence. Linda Montanari, Bruno Guarita

12/13/2016. Gender-sensitive prevention and treatment services for alcohol and drug users in Belgium. 6 What about What we know

OPIOID WORKGROUP LEADERSHIP TEAM

Mission: The Oregon Coalition for Responsible Use of Meds (OrCRM) is a Statewide Coalition launched to prevent overdose, misuse and abuse of

Recent developments in the detection of harms arising from the use of synthetic cathinonesin Europe

Evidence-based interventions for managing illicit drug dependence

Take-home naloxone to prevent heroin/opioid overdose deaths: a UK/Australia shared vision

Coalition Strategies Across The Continuum of Care

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

What do we mean by the opioid crisis? Painkiller prescriptions per 100 North Carolinians Source: CDC US Prescribing Rate Maps (2016)

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Take-Home naloxone: developments and futures. John Strang & Rebecca McDonald National Addiction Centre, King s College London, UK

What difference does it make? Assessing the impact of take-home naloxone scale up internationally

Annual report 2009: the state of the drugs problem in Europe

HIV outbreaks among PWID in Europe linking economic, epidemiological and service provision data -

Identifying local harm reduction priorities: involving drug users and professionals

Peer Naloxone. A harm reduction approach to overdose prevention. Kristel Guthrie RN BScN BA. Chantel Marshall RN BScN. The Works Toronto Public Health

Take Home Naloxone elearning Module Script

Fentanyl: trend-spotting overview and focus on deaths. Jane Mounteney EMCDDA

Efforts to Address the Opioid Epidemic in Clark County

The Challenge of Treating Pain

Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary

Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse

Models of good practice in drug treatment in Europe. Project group

New EU Health Programme: funding mechanisms for civil society working on HIV and related areas

The Opioid Addiction Emergency In Virginia June 8, 2017

Combating Opiate Addiction

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

HARM REDUCTION & THE OPIOID EPIDEMIC. CHELSEA RAINWATER Co-Founder & Executive Director No Overdose Baton Rouge

EMPOWERING CIVIL SOCIETY AND PUBLIC HEALTH SYSTEM TO FIGHT TUBERCULOSIS EPIDEMIC AMONG VULNERABLE GROUPS

Project Meeting Prague

Take Home Naloxone Report on supply and use to reverse an overdose


OPIOIDS IN JACKSON COUNTY A PUBLIC HEALTH PERSPECTIVE OPIOID AWARENESS COUNTY LEADERSHIP FORUM SHELLEY CARRAWAY, HEALTH DIRECTOR DATE

Eliminating Viral Hepatitis in Australia: Where are we in 2017?

Innovative Ways to Fund Harm Reduction Services New Mexico

Insights into shared and specific features of intensive drug use in Europe

HL18.3 REPORT FOR ACTION. Toronto Overdose Action Plan: Prevention & Response SUMMARY

Naloxone-on-Release Guidelines for naloxone provision upon release from prison and other custodial settings

What is the strategy?

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

INTRAVENOUS INJECTING DRUG USE.

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

Methadone Treatment as a Harm Reduction Strategy, Gender Sensitive Programming and Evidence-based Strategies

North Carolina Overdose Prevention Project

HIV AND PEOPLE WHO INJECT DRUGS

From Medicaid Transformation Approved Project Toolkit, June 2017

Workshop summary. Exchange on data collection challenges related to new psychoactive substances use. Presentation of the situation

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

Public Health Association of British Columbia

Opportunities and Challenges for Nursing in WA State Medicaid Expansion and other New Initiatives. Session 2

The drugs situation in Ireland: an overview of trends from 2005 to 2015.

A LOOK AT ABUSE-DETERRENT OPIOIDS

Results from the NPSinEurope.eu Project 5-Country RAR of New Psychoactive Drugs (NPS)

SUBJECT: Opioid Overdose and Intranasal Naloxone Training for Law Enforcement: Train the Trainer Session: Queens County October 17, 2014

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

HARM REDUCTION & TREATMENT. Devin Reaves MSW

New London CARES Coordinated Access, Resources, Engagement and Support

Naloxone (Narcan) Initiatives and the Court System

World Health Organization. A Sustainable Health Sector

Becoming a harm reduction distribution agency in Toronto - information session

Research on opioid overdose and naloxone distribution in San Francisco: from epidemiology to intervention development to implementation.

2 nd Meeting on detecting and responding to outbreaks of HIV among PWID

BRIEFING ON WHY AND HOW TO ADDRESS OVERDOSE IN GLOBAL FUND PROPOSALS

Overall aim Improving the access to and the quality of health and social services for marginalised people

First results collected by Argos, DCR in Strasbourg opened in november 2016

Transcription:

Viewpoints on future dissemination of take-home naloxone: opportunities and challenges Dagmar Hedrich & Isabelle Giraudon, EMCDDA Bergen, 1 September 2015 OVERDOSEKONFERANSEN 2015 ThINCBergen2015: The lnternational Naloxone Conference

EMCDDA reference point on drugs in Europe Specialised EU agency, established 1993, located in Lisbon 30 member countries, incl. Norway Our mission: Provide a factual overview of European drug problems and a solid evidence base to support the drugs debate. - monitoring drug-related deaths: DRD numbers and trends; - responses to reduce DRD, evidence and best practice; - interface to policy making a translational function. emcdda.europa.eu

Overdoses 6000 to 8000 drug-induced deaths per year - Known under-reporting in some countries - Reporting delays - Effect of economic crisis - Stigma and marginalisation Polydrug intoxication is the norm, background of heroin and or other opioids in most cases

Profiles and trends Source EMCDDA EDR 2015 There is no clear decline in overall overdose trends.

Recent increases in some countries Source EMCDDA 2015 EDR

Mortality due to drug-induced deaths among adults (15 64 years). Most recent year reported 140 120 100 80 60 40 20 0 Countries with highest drug-induced mortality rates are in northern Europe

Age pyramids of overdose cases >=65 55-59 50-54 45-49 40-44 35-39 30-34 25-29 20-24 15-19 <15 60-64 Germany 2012 (n=944) Female Male -35 15 65 115 Number of deaths reported >=65 60-64 55-59 50-54 45-49 40-44 35-39 30-34 25-29 20-24 15-19 <15 Ireland 2011 (n=220) -10-5 0 5 10 15 20 25 30 35 40 Number of deaths reported Female Male 45-49 35-39 30-34 25-29 20-24 >=65 60-64 55-59 50-54 40-44 15-19 <15 Estonia 2012 (n=170) Female Male -10 0 10 20 30 40 50 Number of deaths reported >=65 60-64 55-59 50-54 45-49 40-44 35-39 30-34 25-29 20-24 15-19 <15 Norway 2011 (n=262) -15-5 5 15 25 35 Number of deaths reported Femal e

Heroin/opioid trends a mixed picture Drug treatment has been scaled up: now >50% of estimated opioid dependent population in opioid substitution treatment; Broader range of interventions in many countries, e.g. DCRs; Less new recruitment into heroin use; Success of harm reduction measures: new HIV infections among people who inject drugs have declined to all time low; But: Synthetic and semi-synthetic opioids play an increasing role; Heroin using populations are ageing and physically vulnerable; DRD show no clear decline since 2008.

Take-home naloxone Covered by regular EMCDDA monitoring: THN projects operate in DE, DK, EE, ES, IT, NO, UK and are planned in several other countries; Review of evidence (EMCDDA, 2015) Expert meeting Oct 2014

Main challenge: to achieve sufficient coverage of at-risk populations so that substantial reductions in opioid overdose deaths can be attained. Legal/regulatory barriers prescription-only use limited to medically trained personnel handling & storage restricted Technological barrier: Naloxone formulation Injectable (IV, IM, SC) use of syringe an obstacle off-label IN use (by paramedics, in pilot projects) Nasal spray and applicator under development

Information exchange and training: Providing information to policy makers about effectiveness, feasibility and relevance of the intervention Supporting exchange of best practice Promote awareness raising & training Drug users, family and peers Doctors who prescribe OST Low-threshold and treatment staff Prison staff and police

Conclusion Since EMCDDA started monitoring drug-related deaths, 140.000 overdose deaths were reported in Europe; There is evidence that education and training combined with take-home naloxone decreases overdose mortality; Empowering bystanders to deliver a potentially life-saving intervention is an important step in a harm reduction oriented European response to drug use.

Take-home naloxone EMCDDA Insights publication written by John Strang, Rebecca McDonald and colleagues to be launched in 2015. Email for your free copy: publications@emcdda.europa.eu

Thank you for your attention Dagmar Hedrich dagmar.hedrich@emcdda.europa.eu emcdda.europa.eu twitter.com/emcdda facebook.com/emcdda youtube.com/emcddatube flickr.com/photos/emcdda